Immix Biopharma, Inc. (IMMX) Stock Profile — Insider Trades & Financials

Net Income-$10.7M

EPS$-0.61

Market Cap$463.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Ilya Rachman

CEO & Executive Director

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The companyâ lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Founded: 2014
Employees: 21
Headquarters: Los Angeles, California, United States

⚡

Core Efficiency

ROE?

-11.39%

ROA?

-10.19%

D/E Ratio?

0.12

📊

Profitability Ratios

Current Ratio?

10.01

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 19, 2026 (in 132 days)

Annual Report (10-K) — Based on filing pattern

Aug 19, 2026

Predicted10-K

Mar 27, 2026

10-K/AQ4 20257d after period end

Nov 7, 2025

10-QQ3 20252d after period end

Aug 8, 2025

10-QQ2 20257d after period end

May 19, 2025

10-Q/AQ1 202513d after period end

May 19, 2025

10-K/AQ4 202469d after period end

Nov 12, 2024

10-QQ3 20240d after period end

Aug 12, 2024

10-QQ2 20240d after period end

May 9, 2024

10-QQ1 20240d after period end

Loading company sections...

Immix Biopharma, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness